Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 7/20 | 1.00 |
| ▸ | KDM4A | O75164 | 1/20 | 1.00 |
| ▸ | KDM4B | O94953 | 1/20 | 1.00 |
| ▸ | KDM5C | P41229 | 1/20 | 1.00 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 1.00 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 1.00 |
| ▸ | PARP1 | P09874 | 9/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178698 | 0.85 | KDM4A (0.73) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL1891303 | 0.76 | KDM4C (0.61) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL17164124 | 0.74 | KDM4A (0.58) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Quinazolinone SCHEMBL27983253 | 0.74 | PARP1 (1.00) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Quinazolinone SCHEMBL88525 | 0.74 | PARP1 (1.00) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL4949060 | 0.73 | KDM4A (0.57) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL20998623 | 0.72 | PARP1 (0.96) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Quinazolinone SCHEMBL22442340 | 0.72 | PARP1 (0.96) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Quinazolinone SCHEMBL8201420 | 0.72 | PARP1 (0.96) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Quinazolinone SCHEMBL29603643 | 0.72 | PARP1 (0.96) | KDM4CKDM4AKDM4BKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | claimed |
| EP-4072546-B1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIV ANTWERPEN (BE) | 2025-02-19 | — | — | EP | claimed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | claimed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | claimed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | claimed |
| CN-115443276-A | Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors | 东亚ST株式会社 | 2022-12-06 | — | — | CN | claimed |
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | claimed |
| EP-3430008-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114222737-A | Small molecule inhibitor of NF-kB induced kinase | 詹森药业有限公司 | 2022-03-22 | — | — | CN | claimed |
| WO-2017161012-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | claimed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | claimed |
| US-7169926-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-30 | — | — | US | claimed |
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | KDM4C 1153/4885KDM4A 1254/4885KDM4B 1123/4885 |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885KDM4A 11/4885KDM4B 21/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | KDM4C 3330/4885KDM4A 2878/4885KDM4B 2891/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | KDM4C 1839/4885KDM4A 2076/4885KDM4B 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.